Singular Financial Statements From 2010 to 2025
| OMICDelisted Stock | USD 20.01 0.00 0.00% |
Check Singular Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Singular Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Singular financial statements analysis is a perfect complement when working with Singular Genomics Valuation or Volatility modules.
Singular |
Singular Genomics Systems Company Return On Equity Analysis
Singular Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Singular Genomics Return On Equity | -0.54 |
Most of Singular Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Singular Genomics Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Singular Genomics Systems has a Return On Equity of -0.5357. This is 97.77% lower than that of the Health Care Equipment & Supplies sector and 91.04% lower than that of the Health Care industry. The return on equity for all United States stocks is 72.81% higher than that of the company.
Singular Genomics Systems Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Singular Genomics's current stock value. Our valuation model uses many indicators to compare Singular Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Singular Genomics competition to find correlations between indicators driving Singular Genomics's intrinsic value. More Info.Singular Genomics Systems is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Singular Genomics' earnings, one of the primary drivers of an investment's value.About Singular Genomics Financial Statements
Singular Genomics stakeholders use historical fundamental indicators, such as Singular Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Singular Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Singular Genomics' assets and liabilities are reflected in the revenues and expenses on Singular Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Singular Genomics Systems. Please read more on our technical analysis and fundamental analysis pages.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California. Singular Genomics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 248 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Singular Stock
If you are still planning to invest in Singular Genomics Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Singular Genomics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |